Faes Farma, S.A. (BME:FAE)

Spain flag Spain · Delayed Price · Currency is EUR
4.785
0.00 (0.00%)
Apr 28, 2026, 12:12 PM CET
Market Cap1.49B +25.8%
Revenue (ttm)626.99M +22.9%
Net Income79.63M -28.5%
EPS0.25 -28.7%
Shares Out311.26M
PE Ratio18.84
Forward PE15.69
Dividend0.18 (3.74%)
Ex-Dividend DateJan 8, 2026
Volume45,379
Average Volume120,065
Open4.780
Previous Close4.785
Day's Range4.735 - 4.795
52-Week Range4.100 - 5.440
Beta0.32
RSI45.99
Earnings DateApr 30, 2026

About Faes Farma

Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. It engages in chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants services, as well as acquiring, purchasing, disposing of, investing in, holding, using, managing, administering, marketing and leasing corporations, securiti... [Read more]

Sector Healthcare
Founded 1933
Employees 2,681
Stock Exchange Madrid Stock Exchange
Ticker Symbol FAE
Full Company Profile

Financial Performance

In 2025, Faes Farma's revenue was 626.99 million, an increase of 22.93% compared to the previous year's 510.04 million. Earnings were 79.63 million, a decrease of -28.49%.

Financial Statements

News

Faes Farma Earnings Call Transcript: Q4 2025

2025 saw 23% revenue growth, major acquisitions, and strong international expansion, with adjusted EBITDA up 3.1% and net profit down due to one-offs. 2026 guidance targets 17%-19% revenue and 28%-31% EBITDA growth, with continued focus on integration, efficiency, and international markets.

2 months ago - Transcripts

Faes Farma Transcript: M&A Announcement

The acquisition of SIFI accelerates the 2030 growth strategy, expanding the ophthalmology portfolio, global reach, and R&D pipeline. The €270 million deal is expected to be EPS accretive from year one, with strong synergies, high-margin businesses, and limited competition in key areas.

11 months ago - Transcripts

Faes Farma Transcript: CMD 2025

A new leadership team has set an ambitious plan to double sales and nearly double EBITDA by 2030, driven by international expansion, innovation, and targeted M&A. Key investments in R&D, operational excellence, and a new plant support growth, while a renewed culture and sustainability are central to the strategy.

1 year ago - Transcripts